Riluzole is the first drug to be approved for amyotrophic lateral sclerosis (ALS). Riluzole, available as RilutekĀ®, does not cure ALS or improve symptoms, but may extend survival or the time to tracheostomy.
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Slow my ALS progress | 954 |
|
|
|
|
|
95 |
| Other | 16 |
|
1 | ||||
| disease-related symptoms | 16 |
|
|
2 | |||
| General health | 8 |
|
1 | ||||
| Don't know | 7 | 0 | |||||
| Stiffness/Spasticity | 7 | 0 |
See all 984 patients currently taking Riluzole
Mouse over the table for more information
Top 10 dosages based on patients currently taking Riluzole. See all 21 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Side effects too severe
|
77 | 40% |
|
|
Did not seem to work
|
57 | 30% |
|
|
Expense
|
30 | 16% |
|
|
Other
|
27 | 14% |
|
|
Doctor's advice
|
24 | 13% |
|
|
Personal research
|
16 | 8% |
|
|
Not indicated
|
11 | 6% |
|
|
Course of treatment ended
|
4 | 2% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on November 20, 2009.